What is Retatrutide?
Retatrutide (LY3437943) is a triple agonist developed by Eli Lilly that simultaneously activates three different receptors: GLP-1, GIP, and Glucagon. This makes it the most potent peptide in its class for weight regulation.
Why is Retatrutide special?
Unlike Semaglutide (GLP-1 only) and Tirzepatide (GLP-1 + GIP), Retatrutide also activates the glucagon receptor, which increases the body's energy expenditure and fat burning.
How does triple agonism work?
The three mechanisms work synergistically:
- GLP-1: Reduces appetite and delays gastric emptying
- GIP: Improves insulin sensitivity and fat cell metabolism
- Glucagon: Increases basal metabolism and liver fat burning
Dosage & Titration
Note
Retatrutide is more potent than Semaglutide. Always start at the lowest dose and increase gradually. Listen to your body.
Common Side Effects
The side effect profile is similar to other GLP-1 agonists but may be more pronounced due to the triple mechanism:
- Nausea and vomiting (most common in the first weeks)
- Diarrhea or constipation
- Decreased appetite (desired effect)
- Dizziness or headache
- Injection site reaction
Research Results
In Phase 2 studies, Retatrutide showed remarkable results:
Study Results (48 weeks)
- 24.2% weight loss at the highest dose (12mg)
- 17.5% weight loss at intermediate dose (8mg)
- Improved glycemic control
- Significant reduction in liver fat
Phase 3 studies are ongoing and are expected to provide even more detailed data on safety and efficacy.
Conclusion
Retatrutide represents the next generation of weight-regulating peptides. With its unique triple mechanism, it potentially offers the most effective weight loss of all available options. For researchers looking to explore the latest advancements in the field, this is an extremely interesting peptide.
Compare with Semaglutide or Tirzepatide to find the right peptide for your research needs.
```